InvestorsHub Logo
Followers 36
Posts 8284
Boards Moderated 0
Alias Born 04/14/2011

Re: agribusiness72 post# 4886

Friday, 01/08/2021 10:10:28 PM

Friday, January 08, 2021 10:10:28 PM

Post# of 5070
As we wait for Japan's approval I ran across this that I was unaware of: Article from November 2020. Means Revenue started then for Orladeyo!

https://angioedemanews.com/2020/11/09/berotralstat-available-to-eligible-patients-uk-through-early-access-program/


Berotralstat Available to Eligible Patients in UK Through Early Access Program

Berotralstat — an oral therapy by BioCryst Pharmaceuticals for preventing swelling attacks in people with hereditary angioedema (HAE) — will be available to patients, 12 and older, in the U.K. through an Early Access to Medicines Scheme (EAMS) before its potential regulatory approval.

An EAMS gives patient access to therapies not yet approved for commercial use to people with life-threatening or seriously debilitating conditions and a clear unmet medical need.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BCRX News